Delcath Systems Inc - Asset Resilience Ratio

Latest as of December 2025: 38.49%

Delcath Systems Inc (DCTH) has an Asset Resilience Ratio of 38.49% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DCTH total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

$47.58 Million
Cash + Short-term Investments

Total Assets

$123.63 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2002–2025)

This chart shows how Delcath Systems Inc's Asset Resilience Ratio has changed over time. See DCTH net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Delcath Systems Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DCTH market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $47.58 Million 38.49%
Total Liquid Assets $47.58 Million 38.49%

Asset Resilience Insights

  • Very High Liquidity: Delcath Systems Inc maintains exceptional liquid asset reserves at 38.49% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Delcath Systems Inc Industry Peers by Asset Resilience Ratio

Compare Delcath Systems Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
INKON Life Technology Co Ltd
SHE:300143
Medical Devices 3.37%
CareRay Digital Medical Technology Co Ltd
SHG:688607
Medical Devices 16.21%
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
Medical Devices 54.67%
Universus Photo Imagings Limited
NSE:UNIVPHOTO
Medical Devices 30.97%
HansBiomed Corporation
KQ:042520
Medical Devices 9.13%
Aligned Genetics Inc
KQ:238120
Medical Devices 2.22%
Heramed Ltd
AU:HMD
Medical Devices 0.83%
Acarix A/S
ST:ACARIX
Medical Devices 37.81%

Annual Asset Resilience Ratio for Delcath Systems Inc (2002–2025)

The table below shows the annual Asset Resilience Ratio data for Delcath Systems Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 38.49% $47.58 Million $123.63 Million +11.30pp
2024-12-31 27.19% $20.82 Million $76.59 Million -24.11pp
2023-12-31 51.30% $19.81 Million $38.61 Million --
2022-12-31 0.00% $0.00 $17.86 Million --
2011-12-31 14.13% $4.98 Million $35.24 Million +11.18pp
2010-12-31 2.95% $1.49 Million $50.58 Million +0.99pp
2008-12-31 1.96% $222.71K $11.36 Million -25.52pp
2006-12-31 27.48% $2.41 Million $8.76 Million -58.36pp
2005-12-31 85.84% $11.10 Million $12.93 Million -10.12pp
2004-12-31 95.97% $7.06 Million $7.35 Million +12.96pp
2003-12-31 83.00% $2.02 Million $2.43 Million +62.58pp
2002-12-31 20.42% $370.00K $1.81 Million --
pp = percentage points

About Delcath Systems Inc

NASDAQ:DCTH USA Medical Devices
Market Cap
$375.26 Million
Market Cap Rank
#14500 Global
#3265 in USA
Share Price
$10.80
Change (1 day)
+4.05%
52-Week Range
$8.19 - $18.10
All Time High
$1000000.00
About

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more